Equibles does not estimate personal net worth.
Get an email with a short summary when Travere Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TVTX alertsChris Kline is recorded as CFO at Travere Therapeutics, Inc. (TVTX). Chris Kline has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for Travere Therapeutics, Inc. on August 11, 2026. Travere Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Travere Therapeutics, Inc. includes Bradley Campbell (CEO and Board Member), Bradley L. Campbell (CEO and Board Member), Christopher Cline (CFO) and 7 others.
“And before I jump in, we will be making forward-looking statements, so please review our disclosures on our forms 10K and 10Q and less with the SEC. At Trevere, we are exclusively focused on rare disease, and we're a commercial-stage biotech with really a key focus on four main pillars.”
“In the second quarter, we delivered exceptional commercial results, continuing to invest in the programs with the greatest opportunity to create value for patients and shareholders, strategically expanded our pipeline with the addition of ciboribrutinib and strengthened our balance sheet through successful convertible…”
“First on the PSFs and the plan reporting for metrics, no change at this point. We'll, of course, continue to evaluate as we move forward. But the plan for now is to provide aggregate PSFs in revenue.”
“We ended the year in a strong financial position. This was bolstered by continued net product sales growth, focused investment in key priorities to support our current performance and sustainable growth potential, and strategic partner milestones that added to our balance sheet strength.”
Biotechnology · Healthcare
CFO
